Safety of Acetylcholine in the Cath Lab

The concepts of ischemia with non-obstructive coronary artery disease (INOCA) and myocardial infarction with non-obstructive coronary artery disease (MINOCA) have been established, widely spread, accepted, and included in the different guidelines that support our clinical practice. Among INOCA and MINOCA we find vasospastic angina (VSA) caused by epicardial vessel spasms and angina caused by microvascular spasm (MVS), both described as syndrome etiology.

To establish the cause of MINOCA, coronary provocation testing with intracoronary acetylcholine is considered a IIA indication. Specific treatments for these cases might improve patient quality of life, since they often relapse. However, at present, physicians fear potential complications. 

The aim of this study was to assess, through a systematic review and meta-analysis, the safety of coronary provocation testing with intracoronary acetylcholine (ACh) for the contemporary diagnosis of epicardial and microvascular spasm. Major complication was defined as a composite of death, ventricular tachycardia/fibrillation, myocardial infarction, or shock requiring reanimation. Minor complications were paroxysmal atrial fibrillation, ventricular extrasystole, transient hypotension or bradycardia requiring pacemaker implantation. 

This meta-analysis included a total of 16 studies with 12585 patients, the administration of 100 to 200mcg acetylcholine to the left coronary and the assessment of endothelial function with a short 36mcg infusion.

Read also: Prognostic Value of Structural and Functional Microvascular Dysfunction in Patients with Nonobstructive Coronary Artery Disease.

Major complications incidence was 0.5% (CI 95% 0.0-1.3%). There were no deaths. Subgroup analysis showed accumulated incidence of major complications was higher in studies where spasm cutoff value was ≥90% obstruction vs. prior diagnostic cutoff value of ≥75% (1.0%; CI 95% 0.3-2.0%); the incidence was significantly lower in western populations vs. Asian (0.0%; CI 95% 0.0%-0.45%).

When comparing the safety of different doses, major and minor complications rates were similar when using different acetylcholine doses ranging 100 to 200mcg.

Conclusions

Provocation testing with intracoronary acetylcholine resulted safe. There were differences in subgroups, western populations being the least affected. 

Despite the fact that this meta-analysis showed great study heterogeneity, it shows promise towards advancing acetylcholine routine protocols in the cath lab, to better diagnose VSA and MVS as causes of INOCA and MINOCA. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols.

Reference: Takahashi, Tatsunori et al. “Safety of Provocative Testing With Intracoronary Acetylcholine and Implications for Standard Protocols.” Journal of the American College of Cardiology vol. 79,24 (2022): 2367-2378. doi:10.1016/j.jacc.2022.03.385.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...